Literature DB >> 966384

Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

K Aoki, T Yoshida, S Kato, K Tazumi, I Sato.   

Abstract

The Ca2+ antagonistic coronary vasodilator, Nifedipine, was sublingually administered by a dose of 30 mg to 19 patients with hypertension. Blood pressure of patients with with essential hypertension (n=14) decreased from 177 +/- 24 to 123 +/- 13 mmHg systolic and from 108 +/- 12 to 80 +/- 11 mmHg diastolic (mean +/- SD) (p less than 0.01). Plasma renin activity (PRA) increased significantly from 0.73 +/- 0.62 to 1.50 +/- 1.02 ng/ml/h (p less than 0.05). The same tendency was observed in malignant and renovascular hypertension. In primary aldosteronism (n = 2), blood pressure decreased but PRA did not increase. Hypotensive action and increased plasma renin activity by Ca2+ antagonist, Nifedipine, were clearly demonstrated in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 966384     DOI: 10.1536/ihj.17.479

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  21 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium antagonists. Clinical use in the treatment of systemic hypertension.

Authors:  C Spivack; S Ocken; W H Frishman
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

3.  Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension.

Authors:  M Thibonnier; F Bonnet; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

Review 4.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

5.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension.

Authors:  K Aoki; K Sato; Y Kawaguchi; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention.

Authors:  I Azimi; S J Roberts-Thomson; G R Monteith
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.

Authors:  K P Ohman; L Weiner; H von Schenck; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Hemodynamic effects of Ro 23-6152 in patients with essential hypertension.

Authors:  H B Folkers; J C van Zwienen; P Boer; C H Kleinbloesem; G G Geyskes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Treatment of severe hypertension and hypertensive crises with nifedipine.

Authors:  M C Houston
Journal:  West J Med       Date:  1987-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.